Vcinity adds Dr. Robin Smith to its Board of Directors

– USA, CA –  Vcinity, Inc., a company empowering the edge and redefining cloud, today announced the appointment of business leader, entrepreneur, medical doctor, and philanthropist Dr. Robin Smith, MD to its Board of Directors. Dr. Smith is uniquely positioned to guide and assist Vcinity during its current phase of growth and into the future.

Dr. Smith is a pioneer in the fields of regenerative medicine and predictive analytics and brings a rare combination of understanding disruptive innovation and business acumen to drive interest and growth. Previously as a Chairman and CEO of Neostem (NASDAQ: NBS), she transformed the company’s proprietary cell therapy development into an innovative business model, which led to its acquisition by Hitachi at 8x the price it had been acquired.

“Dr. Smith is a trailblazer in the healthcare innovation space, and we are absolutely honored and thrilled to welcome her to Vcinity’s Board of Directors,” said CEO, Harry Carr. “Her experience with driving business innovation and growth will be extremely valuable as Vcinity transitions to a growth phase.”

About Dr. Robin Smith

She is an accomplished author on the topic of cell therapeutics. She has received many accolades for her tireless efforts in the healthcare industry, which include; the Regenerative Medicine Foundation 2019 Stem Cell and Regenerative Medicine Action Award for International Diplomacy, the 2018 HEALinc Future Health Humanitarian Award, the Business Intelligence Group’s Woman of the Year Award in 2018 and the 2018 Gold Stevie® Award for Woman of the Year – Government or Non-profit. In April 2016, Pope Francis awarded Dr. Smith Dame Commander with Star Pontifical Equestrian Order of Saint Sylvester Pope and Martyr. In May 2017, she was also awarded the Lifetime Achievement in Healthcare and Science Award by The National Museum of Catholic Art and Library. Dr. Smith was appointed as clinical associate professor, Department of Medicine at the Rutgers, New Jersey Medical School in 2017.

Dr. Smith currently serves on the boards of Sorrento Therapeutics (NASDAQ: SRNE), ServiceSource International, Inc. as well as Celularity Inc, a Celgene spin-out focused on cancer and regenerative medicine. She is also active in many nonprofit organizations such as the Cura Foundation and Stem for Life. She serves as a member of the Board of Trustees of the Sanford Health International Board, the Alliance for Regenerative Medicine Foundation, Unite to Prevent Cancer Foundation and the Alliance for Cell Therapy Now. She also serves on the Board of Overseers of the New York University Langone Medical Center in New York. She previously served on the Board of Trustees of the New York University Langone Medical Center and was Chairman of the Board of Directors of the New York University Hospital for Joint Diseases.

“Vcinity is at an interesting crossroads after having developed and deployed unique technology to transform wide area networks into a global LAN for its customers. Their innovative solutions are germane to a number of market verticals, and I am particularly excited to think about the possibilities to drive digital transformation across the healthcare and pharmaceutical industries,” commented Dr. Smith.

Dr. Smith received her B.A. degree from Yale University and her M.D. degree from the Yale School of Medicine. She holds an M.B.A. degree from the Wharton School of Business and completed the Stanford University Directors Program. In 2019, she received an honorary Doctor of Science degree from Thomas Jefferson Medical College.

About Vcinity inc.

Vcinity enables digital transformation by providing enterprises an ability to instantly access and operate on data sets over any distance, without copying them and with local like performance. We accomplish this by transforming your WAN into a Global LAN and supporting local application performance on data over global distances while eliminating copy sprawl and edge caching. These capabilities let enterprises spend time and money on business innovation driving competitive advantage.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.